CoChat
Sign Up
Cited by 18

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

High-risk HPV16E6 stimulates hADA3 degradation by enhancing its SUMOylation

Chand, Vaibhav, John, Rince, Jaiswal, Neha, Johar, Sumreet S., Nag, Alo·2014·Carcinogenesis
DOI 10.1093/carcin/bgu104
Open this paper in CoChat — free account

Abstract

Despite significant research, our understanding of the molecular mechanisms of Human Papilloma Virus (HPV) induced cancers remains incomplete. Majority of invasive cervical cancers are caused by high-risk HPV 16 and 18. Two potent HPV oncoproteins, E6 and E7, promote human malignancies by disrupting the activities of key regulators of cell proliferation and apoptosis. Recent investigations have identified hADA3, a transcriptional coactivator protein as a target of high-risk HPV16E6. However, the mechanism of degradation of hADA3 by E6 and its contribution in HPV induced carcinogenesis is poorly understood. Here, we showed that E6-mediated proteolysis of hADA3 is responsible for maintaining low levels of hADA3 in HPV-positive cervical cancer cell lines. We demonstrate that HPV16E6 targets hADA3 for ubiquitin-mediated degradation via E6AP ubiquitin ligase. We also show that hADA3 undergoes accelerated SUMOylation in the presence of HPV16E6. Our data represent the first evidence that hADA3 is posttranslationally modified by SUMOylation, which makes it unstable and establishes a link between SUMOylation and E6-mediated ubiquitination of hADA3. Furthermore, depletion of Ubc9 prevented rapid degradation of hADA3 in E6 expressing cervical cancer cells and overexpression of hADA3 resulted in suppression of proliferation and migration abilities of SiHa cells. Overall, this study underscores the importance of posttranslational modifications in HPV16E6-mediated downregulation of hADA3 t…

Overview

Integrity signals

Registry

Crossref · 10.1093/carcin/bgu104

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 40

  1. Münger, (2002), Human papillomavirus immortalization and transformation functions, Virus Res., 89, 213, 10.1016/S0168-1702(02)00190-9 · DOI
  2. zur Hausen, (2008), Papillomaviruses—to vaccination and beyond, Biochemistry, 73, 498
  3. Moody, (2010), Human papillomavirus oncoproteins: pathways to transformation, Nat. Rev. Cancer, 10, 550, 10.1038/nrc2886 · DOI
  4. Scheffner, (1993), The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53, Cell, 75, 495, 10.1016/0092-8674(93)90384-3 · DOI · Paper page
  5. Münger, (1989), Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product, EMBO J., 8, 4099, 10.1002/j.1460-2075.1989.tb08594.x · DOI · Paper page
  6. Dyson, (1989), The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product, Science, 243, 934, 10.1126/science.2537532 · DOI · Paper page
  7. Münger, (1989), The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes, J. Virol., 63, 4417, 10.1128/JVI.63.10.4417-4421.1989 · DOI · Paper page
  8. Werness, (1990), Association of human papillomavirus types 16 and 18 E6 proteins with p53, Science, 248, 76, 10.1126/science.2157286 · DOI · Paper page
  9. Boyer, (1996), E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway, Cancer Res., 56, 4620
  10. Reznikoff, (1996), Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells, Cancer Res., 56, 2886
  11. Veldman, (2003), Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter, Proc. Natl Acad. Sci. USA, 100, 8211, 10.1073/pnas.1435900100 · DOI · Paper page
  12. Kumar, (2002), Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3, Mol. Cell. Biol., 22, 5801, 10.1128/MCB.22.16.5801-5812.2002 · DOI · Paper page
  13. Nag, (2007), An essential role of human Ada3 in p53 acetylation, J. Biol. Chem., 282, 8812, 10.1074/jbc.M610443200 · DOI
  14. Sekaric, (2007), hAda3 regulates p14ARF-induced p53 acetylation and senescence, Oncogene, 26, 6261, 10.1038/sj.onc.1210462 · DOI · Paper page
  15. Shamanin, (2008), hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells, J. Virol., 82, 3912, 10.1128/JVI.02466-07 · DOI
  16. Mohibi, (2012), Mammalian alteration/deficiency in activation 3 (Ada3) is essential for embryonic development and cell cycle progression, J. Biol. Chem., 287, 29442, 10.1074/jbc.M112.378901 · DOI
  17. Zeng, (2002), Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator, J. Biol. Chem., 277, 45611, 10.1074/jbc.M208447200 · DOI
  18. Meng, (2004), Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation, J. Biol. Chem., 279, 54230, 10.1074/jbc.M404482200 · DOI
  19. Ogryzko, (1998), Histone-like TAFs within the PCAF histone acetylase complex, Cell, 94, 35, 10.1016/S0092-8674(00)81219-2 · DOI
  20. Wang, (2001), hADA3 is required for p53 activity, EMBO J., 20, 6404, 10.1093/emboj/20.22.6404 · DOI
  21. Martinez, (2001), Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo, Mol. Cell. Biol., 21, 6782, 10.1128/MCB.21.20.6782-6795.2001 · DOI
  22. Germaniuk-Kurowska, (2007), Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation, Cancer Res., 67, 11789, 10.1158/0008-5472.CAN-07-2721 · DOI
  23. Nag, (2001), DDB2 induces nuclear accumulation of the hepatitis B virus X protein independently of binding to DDB1, J. Virol., 75, 10383, 10.1128/JVI.75.21.10383-10392.2001 · DOI
  24. Leng, (2003), Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation, Cell, 112, 779, 10.1016/S0092-8674(03)00193-4 · DOI
  25. Berns, (2004), A large-scale RNAi screen in human cells identifies new components of the p53 pathway, Nature, 428, 431, 10.1038/nature02371 · DOI
  26. Yokota, (2007), Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9, J. Biol. Chem., 282, 1998, 10.1074/jbc.M607741200 · DOI
  27. Kühne, (1998), E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box, J. Biol. Chem., 273, 34302, 10.1074/jbc.273.51.34302 · DOI
  28. Gao, (2002), Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase, Cancer Res., 62, 3315
  29. Nakagawa, (2000), Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase, Mol. Cell. Biol., 20, 8244, 10.1128/MCB.20.21.8244-8253.2000 · DOI · Paper page
  30. Hu, (2009), HPV16 E6-induced and E6AP-dependent inhibition of the transcriptional coactivator hADA3 in human cervical carcinoma cells, Cancer Invest., 27, 298, 10.1080/07357900802350798 · DOI
  31. Geiss-Friedlander, (2007), Concepts in sumoylation: a decade on, Nat. Rev. Mol. Cell Biol., 8, 947, 10.1038/nrm2293 · DOI
  32. Shuai, (2006), Regulation of cytokine signaling pathways by PIAS proteins, Cell Res., 16, 196, 10.1038/sj.cr.7310027 · DOI
  33. Klug, (2013), Ubc9 sumoylation controls SUMO chain formation and meiotic synapsis in Saccharomyces cerevisiae, Mol. Cell, 50, 625, 10.1016/j.molcel.2013.03.027 · DOI
  34. Drag, (2008), DeSUMOylating enzymes–SENPs, IUBMB Life, 60, 734, 10.1002/iub.113 · DOI
  35. Everett, (2006), PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0, J. Virol., 80, 7995, 10.1128/JVI.00734-06 · DOI
  36. Tatham, (2008), RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation, Nat. Cell Biol., 10, 538, 10.1038/ncb1716 · DOI
  37. Cheng, (2007), SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia, Cell, 131, 584, 10.1016/j.cell.2007.08.045 · DOI · Paper page
  38. Thomas, (1998), Inhibition of Bak-induced apoptosis by HPV-18 E6, Oncogene, 17, 2943, 10.1038/sj.onc.1202223 · DOI · Paper page
  39. John, (2011), Genotoxic stress induced posttranslational modification of transcriptional adaptor protein Ada3, J Proteins Proteom, 2, 71
  40. Wilson, (2012), Sumoylation at the Host-Pathogen Interface, Biomolecules, 2, 203, 10.3390/biom2020203 · DOI

Cited by

See all 18

Metadata

Authors
Chand, V., John, R., Jaiswal, N., Johar, S. S., & Nag, A.
Venue
Carcinogenesis
Publisher
Oxford University Press (OUP)
Published
2014-05-02
Volume
35
Issue
8
Pages
1830-1839
ISSN
  • 1460-2180
  • 0143-3334
DOI
10.1093/carcin/bgu104
Cited by
18
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review